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OBJECTIVES: HbA1c drift is the gradual loss of treatment efficacy typically for oral 
anti-diabetic drugs. Modeling studies including the effects of HbA1c drift in oral 
anti-diabetic drugs are rare in the literature. Clinical outcomes can be distorted if 
the drifts are not considered. Our study compared the simulated clinical outcomes 
of type 2 diabetic mellitus (T2DM) treatments with and without drift. METHODS: 
Lifetime clinical outcomes of treatments were estimated using a Monte Carlo 
microsimulation model. The simulated cohort was newly diagnosed age 45 T2DM 
patients with an initial 8.5% HbA1c level. Demographic and clinical characteristics 
were sourced from NHANES data. Two scenarios were simulated. Both scenarios 
were aligned with Vijan et al., 2014. The first scenario compared the benefit of met-
formin with and without drift over a stable HbA1c of 8.5%. The second compared 
metformin with drift to basal-bolus insulin. Drift data were extrapolated from 
clinical trials. RESULTS: Metformin treatment without drift gained 3.02 life years 
(LY), while with drift the LY gain was only 0.08. For 100,000 simulated patients, 
metformin without drift prevents 1,960 myocardial infarctions (MIs), 320 strokes, 
10,610 cases of blindness, 27,390 lower extremity amputations (LEAs), and 19,010 
end stage renal disease cases requiring dialysis (ESRDs). When HbA1c drift was 
considered, the benefits of metformin treatment shrank to no additional strokes, 
prevention of 500 cases of blindness, 700 LEAs, and 410 ESRDs, with an increase 
of 100 MIs. The direct comparison of LY of metformin with drift and insulin treat-
ment showed that the insulin gained 2.51 LY over metformin. Compared with 
metformin treatment with drift, insulin treatment prevented more complication 
events including 2,110 MIs, -140 strokes, 8,340 cases of blindness, 20,450 LEAs, and 
16,390 ESRDs. CONCLUSIONS: HbA1c drift in oral anti-diabetic drugs has substan-
tial effects on clinical outcomes and should be incorporated into diabetes health 
outcome models.
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OBJECTIVES: Type 2 Diabetes(T2D) has multiple comorbid complications. Early 
detection of T2D can delay and prevent these complications. We study the preva-
lence and timing of occurrence of complications of diabetes including cardiovas-
cular, cerebrovascular, renal, and eye complications, for patients newly-diagnosed 
with T2D. METHODS: We studied a cohort of 4.1million insurance beneficiaries 
of age≥ 18yrs with recorded claims between 2005 and 2013. Among them 26,778 
patients were newly diagnosed with T2D, and had continuous enrollment for 3-years 
prior-to- and 1-year post-T2D diagnosis. We defined diabetes complications based 
on the diabetes complications severity index. We assessed number and percentages 
of patients with each complication, in total, and in relation to time of T2D diagno-
sis. RESULTS: Among 26,778 patients newly diagnosed with T2D, 13,538 had at least 
one complication during the observation period. Of these patients, 9,526(70%) had 
it before T2D diagnosis and 1,102(8%) had it within 6months after T2D diagnosis. A 
total of 10,143 patients had cardiovascular complications during observation period. 
Of these patients, 7,338(72%) had them before T2D diagnosis, and 720(7%) had them 
within 6months after T2D diagnosis. A total of 3,686 patients had cerebrovascular 
complications during observation period. Of these patients, 2,222(60%) had them 
before T2D diagnosis, and 294(8%) had them within 6months after T2D diagnosis. A 
total of 4,358 patients had renal complications during observation period. Of these, 
2,215(50%) had them before T2D diagnosis, and 517(11%) had them within 6months 
after T2D diagnosis. A total of 2,286 patients had eye complications during study 
period. Of these patients, 928(40%) had them before T2D diagnosis, and 355(14%) had 
them within 6months after T2D diagnosis. CONCLUSIONS: In our cohort, conditions 
associated with long-term complications of diabetes were commonly diagnosed 
before or soon after T2D diagnosis date. Better approaches for early detection and 
treatment of T2D are needed, to prevent or delay its complications.
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OBJECTIVES: The literature documents that patients with diabetes have greater 
risks of developing dementia, suggesting that antidiabetic agents might lower the 
risk of dementia. However, it remains unclear about the roles of specific anti-dia-
betic drug classes in developing dementia in the elderly. Furthermore, traditional 
methodology of capturing dementia using claims data alone in observational 
studies are subject to significant underestimation of dementia. The objective 
of this study is to explore the association between specific anti-diabetic drugs 
and the risk of dementia or Alzheimer’s diseases (AD) identified by an improved 
methodology among the elderly. METHODS: A retrospective cohort study was 
conducted using data from the Medicare Current Beneficiary Survey (MCBS) 
linked to the Medicare claims from 2001 to 2010. The study sample consisted of 
Medicare beneficiaries aged> 65 years and were diagnosed with diabetes. Anti-
diabetic medications, both insulins and oral anti-diabetic agents, were identified 
from the prescription medication file. Dementia or AD was determined based 
on the patients’ self-reports, diagnosis codes in Medicare claims, or dementia-
targeted medications during 2-year follow up period to identify incident dementia. 
Multivariable logistic regressions were used to estimate the association between 
anti-diabetic drugs and dementia. Cross-sectional weights were used to adjust for 
the complex survey design. RESULTS: Overall, after adjusting for demographics, 
from 2011-2013 we selected a cohort of men diagnosed with hypogonadism 
who had no evidence of hypogonadism in a six month pre period. These men 
were divided into those who received injectable testosterone therapy (case-T) 
and those who did not (control-NT). For analysis three controls were selected for 
each case using Greedy matching on age, race, Charleson comorbidity index (CCI), 
presence of hypercholesteremia and hypertension. Each cohort was followed for 
two years identifying outcomes including: gynecomastia, abnormal weight gain, 
stroke, myocardial infarction (MI), osteopenia, and osteoporosis. Median time to 
event was calculated for each group. Kaplan-Meyer curves with Wilcoxon tests 
were used to compare time to event for each disease. RESULTS: 1625 cases were 
identified as well as 4794 Greedy matched controls. T-test and chi-square analysis 
on all matching criteria showed no difference between the two groups at base-
line. Kaplan-Meyer analysis associated testosterone therapy with delayed time in 
months to event in osteoporosis (T= 7 months, NT= 4 months, p= 0.01)), osteope-
nia (T= 9 months, NT= 7 months, p= 0.04), and MI (T= 13 months, NT= 10 months, 
p= 0.04). CONCLUSIONS: Injectable testosterone therapy was shown to delay time 
to event for osteoporosis, osteopenia, and MI while not increasing the occur-
rence of stroke or MI. This study has shown that with long follow up injectable 
testosterone therapy delays the negative effects of hypogonadism in older men.
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OBJECTIVES: The association between rare genetic disorders, hereditary fructose 
intolerance (HFI) or alpha-1 antitrypsin deficiency (A1AT), and type 2 diabetes 
(T2D) has not yet been investigated. Therefore, the objective of this undertaking 
was to evaluate the association between both genetic disorders and T2D using 
four large observational databases and adjust for ascertainment bias. METHODS: 
Patients with a HFI diagnosis (ICD-9: 271.2) or A1AT diagnosis (ICD-9: 273.4) and 
T2D diagnosis (ICD-9: 250.x0 or 250.x2) were identified in the Truven MarketScan 
Claims Database (2007-2012), Optum Claims Database (2002-2012), Humedica 
Electronic Health Records (EHR) Database (2007-2012), and GE Centricity EHR 
Database (1995-2012). The association between both genetic disorders and T2D 
was compared to the association between T2D and seven negative control chronic 
diseases with no established relationship with T2D. RESULTS: The unadjusted 
association between both genetic disorders and T2D was positive and hetero-
geneous (p< 0.001) in all four databases. The unadjusted pooled odds ratio (OR) 
calculated using a random-effects model meta-analysis was 3.48 (95% CI: 2.21-
5.46) for HFI and 2.71 for A1AT (95% CI: 1.75-4.20). After pooling all patients and 
adjusting for the negative controls using a random-effects model meta-analysis, 
it was found that HFI patients have a 73% increased odds of T2D (ratio of odds 
ratios [ROR]= 1.73, 95% CI: 1.08-2.75) compared to patients with negative control 
diseases; the association was stronger when utilizing a fixed-effects model meta-
analysis (ROR= 2.19, 95% CI: 2.07, 2.31). The adjusted association between A1AT and 
T2D was statistically significant in the fixed-effects (ROR= 1.33, 95% CI: 1.27-1.40) 
model meta-analysis but not the random-effects model meta-analysis (ROR= 1.35, 
95% CI: 0.86, 2.12). CONCLUSIONS: HFI and T2D were positively associated after 
adjustment for negative control chronic diseases in both meta-analysis models. 
Rare disease researchers using observational data to conduct comorbidity analyses 
can utilize negative controls and multiple datasets to account for ascertainment 
bias and database heterogeneity, respectively.
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OBJECTIVES: Type 2 Diabetes(T2D) and its comorbid conditions are imposing large 
burdens on health-care systems worldwide. Once a patient is diagnosed with T2D, 
their risk for immediate chronic comorbid conditions is less quantified. We aim 
to build risk prediction models for onset of cardiovascular, cerebrovascular, renal 
and eye severe conditions for newly-diagnosed patients with T2D. METHODS: Our 
cohort includes 4.1million insurance beneficiaries of age≥ 18yrs between 2005 and 
2013. Of these subjects, 34,411 patients were newly-diagnosed with T2D, had con-
tinuous enrollment for 6months pre- and 5years post-onset, and did not have the 
comorbid condition diagnosis before T2D. We developed a prediction model for 
each condition based on L1-regularization method, which selects few(less than 
350 per condition) relevant risk factors from approximately 27K general variables 
derived from claims data. We defined comorbid conditions based on the validated 
diabetes complications severity index. RESULTS: For patients newly-diagnosed 
with T2D, we can predict new onset of cardiovascular conditions with Area Under 
Curve(AUC)= 0.69±1e-4; cerebrovascular conditions with AUC= 0.73±1e-4; renal com-
plications with AUC= 0.71±1e-4; eye conditions with AUC= 0.65±1e-4. Our method 
discovers risk factors, some of which have significant (p≤ 0.001) differences in odds 
ratios(OR) between genders/age subgroups. Top differences include: High albumin 
in blood for middle-aged patients(40≤ age< 65yrs) (male-OR 1.3[0.9-1.9] vs. female-
OR 2.1[1.5-3.4]) in cardiovascular events; High erythrocyte distribution width in old 
patients(age> 65) (male-OR 1.6[1.3-2.1] vs. female-OR 1[0.8-1.2]) in cerebrovascular 
events; High creatinine in middle aged patients (male-OR 4.6[3.4-6.0] vs. female-
OR 5.7[4.1-7.9]), high urea nitrogen for middle-age patients (male-OR 2.2[1.7-2.7] 
vs. female-OR 2.7[2.11-3.5]), and decreasing thyrotropin for old patients (male-OR 
1.1[0.9-1.5] vs. female-OR 0.6[0.4-0.7]) in renal events. CONCLUSIONS: Our proposed 
model shows promise in risk prediction and risk factor discovery for 4 comorbid 
complications of T2D in patients newly-diagnosed with T2D. Further research is 
needed to understand how these predictions translate to prevention and delay of 
the complications onset.
